StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Celgene (CELG) Says Results from First Phase III Trial of Oral Ozanimod Versus an Active Comparator in Relapsing MS Presented at MSParis2017
October 27, 2017 9:06 AM
Celgene Corporation (NASDAQ: CELG) today announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Celgene (CELG) Remains In The Good Graces of Oppenheimer
October 27, 2017 11:09 AM
Mizuho is Positive on Celgene (CELG)
October 27, 2017 10:31 AM
Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTR
October 27, 2017 9:05 AM
